Author:
Wang Han,Liu Junjie,Lou Yanyan,Liu Yang,Chen Jieqing,Liao Xinhui,Zhang Xiuming,Zhou Chengzhi,Mei Hongbing,Tang Aifa
Abstract
AbstractBladder cancer (BC) is a crisis to human health. It is necessary to understand the molecular mechanisms of the development and progression of BC to determine treatment options. Publicly available expression data were obtained from TCGA and GEO databases to spot differentially expressed genes (DEGs) between cancer and normal bladder tissues. Weighted co-expression networks were constructed, and Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Associations in hub genes, immune infiltration, and immune therapy were evaluated separately. Protein–protein interaction (PPI) networks for the genes identified in the normal and tumor groups were launched. 3461 DEGs in the TCGA dataset and 1069 DEGs in the GSE dataset were identified, including 87 overlapping genes between cancer and normal bladder groups. Hub genes in the tumor group were mainly enriched for cell proliferation, while hub genes in the normal group were related to the synthesis and secretion of neurotransmitters. Based on survival analysis, CDH19, RELN, PLP1, and TRIB3 were considerably associated with prognosis (P < 0.05). CDH19, RELN, PLP1, and TRIB3 may play important roles in the development of BC and are potential biomarkers in therapy and prognosis.
Funder
Shenzhen Science and Technology Innovation Commission Technology Tackling Project
National Key research and development projects
The Shenzhen Science and Technology Project
The National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
2. Ghervan, L. et al. Small-cell carcinoma of the urinary bladder: Where do we stand?. Clujul Med. 90(1), 13–17 (2017).
3. Karakiewicz, P. I. et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 97(5), 997–1001 (2006).
4. Jacobs, B. L., Lee, C. T. & Montie, J. E. Bladder cancer in 2010: How far have we come?. CA Cancer J. Clin. 60(4), 244–272 (2010).
5. Ploeg, M., Aben, K. K. & Kiemeney, L. A. The present and future burden of urinary bladder cancer in the world. World J. Urol. 27(3), 289–293 (2009).